Monday 23 May – 01:00 pm - 09:00 pm

- **REGISTRATION starts at 01:00 pm**

01:15 pm - 02:30 pm – VEGF Consortium (closed meeting)

02:30 pm - 03:30 pm – Consortium MAST4HEALTH & GUTENBERG (closed meeting)

03:30 pm - 04:30 pm – 1st dedicated poster session

04:30 pm - 05:00 pm – **WELCOME** – Sofia SIEST, Nancy, France

05:00 pm - 06:30 pm – **KEYNOTE ROUND TABLE** – **PGx ANALYSIS IN THE MEDICAL DIAGNOSTIC LABORATORY - FROM SCIENCE TO CLINICAL DECISION SUPPORT (CDS)**

Chairs: Raute Sunder-Plassman, Vienna, Austria / Markus Paulmichl, Salzburg, Austria

**Topics:**

1. Current PGx research - Munir Pirmohamed, Liverpool, United Kingdom

2. Preemptive PGx - Ron van Schaik, Rotterdam, The Netherlands

3. Diagnostic strategies in PGx - Magnus Ingelman-Sundberg, Stockholm, Sweden

4. PGx reports:
   - Magnus Ingelman-Sundberg, Stockholm, Sweden
   - Raute Sunder-Plassman, Vienna, Austria

5. Clinical decision support systems - Vangelis Manolopoulos, Alexandroupolis, Greece

6. Standardization in PGx diagnostics - Markus Paulmichl, Salzburg, Austria
06:30 pm - 07:30 pm – KEYNOTE LECTURE
Chairs: Georges Dagher, Paris, France / Sofia Siest, Nancy, France

Nickolas Papadopoulos, Baltimore, US - Advances in Cancer Detection

Welcome reception – 07:30 pm - 09:00 pm at the Petros Nomikos Center

Tuesday 24 May – 09:00 am - 01:30 pm

09:00 am – 11:00 am – SESSION I – LIQUID BIOPSY, PAST, PRESENT, FUTURE
Chairs: Heiko Meyer, Hamburg, Germany / Georges Dagher, Paris, France

SPONSORED BY AGENA

09:00 am - 09:30 am
Klaus Pantel, Hamburg, Germany – Liquid Biopsy: From Discovery to Clinical Implementation

09:30 am - 10:00 am
Catherine Alix-Panabieres, Montpellier, France - Metastasis-Competent circulating tumor cells in colon cancer

10:00 am - 10:30 am
Ed Schuuring, Gröningen, The Netherlands - Detection of clinically actionable mutations in NSCLC: is there a one-fits-all cell-free DNA test for routine clinical practice?

10:30 am - 11:00 am
Michael Oellerich, Götingen, Germany – Donor-derived cell-free DNA testing in organ transplantation: a value proposition

11:00 am - 11:30 am – Coffee Break

11:30 am – 01:30 pm – FLASH COMMUNICATIONS SESSION
Chairs: Michael Marschler, Henstedt-Ulzburg, Germany / Vangelis E. Manolopoulos, Alexandroupolis, Greece

11:30 am – 11:45 am
Csilla Sipeky, Turku, Finland – Personalised medicine of prostate cancer

11:45 am – 12:00 pm
Janja Marc, Ljubljana, Slovenia – Why men have stronger bones? Genetic background

12:00 pm – 12:15 pm
Milica Medic-Stojanoska, Nova Sad, Serbia – Polycystic ovary syndrome: do phthalates and bisphenol A play role?

12:15 pm – 12:30 pm
Sanja Stankovic, Belgrade, Serbia – Association between CYP2C19 polymorphisms and clinical outcomes in STEMI patients treated by PPCI

12:30 pm – 12:50 pm
Andrea Griesmacher, Innsbrück, Austria – Pharmacogenetics and immunosuppressive drugs in clinical daily life

12:50 pm – 01:10 pm
Ingolf Cascorbi, Kiel, Germany – Pharmacogenomics of tyrosine kinase inhibitors

01:10 pm – 01:30 pm
Vangelis Manolopoulos, Alexandroupolis, Greece – Pharmacogenetics and personalised medicine in anticoagulation latest developments.

01:30 pm – 02:30 pm – LUNCH TIME

02:00 pm - 03:00 pm – 2nd dedicated poster session
Tuesday 24 May – 03:00 pm - 04:00 pm

03:00 pm – 04:00 pm – SESSION II – ADVANCES ON CELLULAR AND MULTI-OMIC APPROACHES
Chairs: Carlos Malpica, Doha, Qatar / Robert Barouki, Paris, France

03:00 pm - 03:30 pm
Colin Brenan, Boston, Massachusetts, United States – Single cell omics

03:30 pm - 04:00 pm
Ekaterini Alexiou Chatzaki, Alexandroupolis, Greece – Biomarker discovery in the era of automated machine learning: from targeted to data-driven approaches

04:00 pm - 5:00 pm General Assembly of the Santorini Conferences (SCs) association

9:00 pm – Gala dinner

Wednesday 25 May – 09:30 am - 01:30 pm

09:30 – 11:00 am – SESSION III – HEART INFLAMMATION
Chairs: Panagiotis Deloukas, London, United Kingdom / John Lamont, Crumlin, County Antrim, United Kingdom

SPONSORED BY RANDOX

09:30 am - 10:00 am
Federica Marelli-Berg, London, United Kingdom - Preservation of microvascular barrier function requires CD31 receptor-induced metabolic reprogramming

10:00 am - 10:30 am
Shoumo Bhattacharya, Oxford, United Kingdom – Therapeutic targeting of the chemokine network in inflammation using tick salivary proteins

11:00 am – 11:30 – Coffee Break

11:30 am – 12:30 pm – SESSION IV – ECON-OMICS: BETTER CARE FOR BETTER COST
Chairs: Georges Dagher, Paris, France / Robin Everts, San Diego, United States

11:30 am – 12:00 pm
Georges Dagher, Paris, France – Big data, AI and Ethics

12:00 pm - 12:30 pm
Uwe Oelmueller, Hilden, Germany

12:30 pm – 01:30 pm – SESSION V - 1st part – GENETIC SCREENING & CLINICAL APPLICATIONS
Chairs: Guillaume Paré, Hamilton Canada / Georges Dedoussis, Athens, Greece

12:30 pm - 01:00 pm
Philippe Froguel, Lille, France - Impact of rare variants in metabolic diseases towards personalized medicine

01:00 pm - 01:30 pm
Georges Dedoussis, Athens, Greece – Omics and Mastiha treatment in NAFLD - The EU Mast4Health program

01:30 pm - 02:30 pm – LUNCH TIME
Wednesday 25 May – 02:30 pm - 06:00 pm

02:30 pm – 04:30 pm – SESSION V – 2nd part – GENETIC SCREENING & CLINICAL APPLICATIONS
Chairs: Guillaume Paré, Hamilton Canada / Sofia Siest, Nancy, France

02:30 pm - 03:00 pm
- Panagiotis Deloukas, London, United Kingdom – Cardiovascular disease prediction & polygenic risk scores

03:00 pm - 03:30 pm
- Guillaume Paré, Hamilton Canada – The rise of the polygenic risk score: Phoenix or Icarus?

03:30 pm - 04:00 pm
- Robert Barouki, Paris, France – The relevance of non-genomic stressors: deciphering environmental factors for the next decade

04:00 pm - 04:30 pm
- Stavroula Kanoni, London, United Kingdom – Genetic susceptibility for COVID-19 infection and severity

04:30 pm - 06:00 pm – SELECTED ABSTRACTS - ORAL COMMUNICATIONS SESSION
Chairs: Csilla Sipeky, Turku, Finland / Belgin Süsleyici, Istanbul, Turkey


- Alex Chenchik, Mountain View, US - Cell Barcoding, Genetic Screens and Expression Profiling at a Single-cell Level

- Frances T. Yen, Vandoeuvre-lès-Nancy, France - Molecular mechanisms underlying dyslipidemias as risk factors for Alzheimer's disease

- Stavroula Kanoni, London, United Kingdom - Evidence of nutrigenetic modulation of oxidation levels among NAFLD patients receiving Mastiha in the Mast4Health clinical trial

Thursday 26 May – 09:00 am - 01:00 pm

09:00 am – 10:00 am – SESSION VI – DIGITAL HEALTH
Chairs: Alexander Haliassos, Athens, Greece / Michael Marschler, Henstedt-Ulzburg, Germany

09:00 am – 09:30 am
- Alexander Haliassos, Athens, Greece – Mobile Health (mHealth) and Internet of Things (IoT)

09:30 am - 10:00 am
- Ivan Brandslund, Odense, Denmark – AI in Cancer, Emergency and COVID-19
10:00 am - 10:30 am – Coffee Break

10:30 am - 01:00 pm – SESSION VII – PHARMACOGENOMICS AND POST-MARKETING APPLICATIONS
Chairs: Charity Nofziger, Salzburg, Austria / Vangelis Manolopoulos, Alexandroupolis, Greece

10:30 am - 11:00 am
Ron van Schaik, Rotterdam, The Netherlands – Pharmacogenetics testing in a health care system: opportunities and challenges

11:00 am - 11:30 am
Charity Nofziger, Salzburg, Austria – Efforts of the Pharmacogene Variation Consortium (PharmVar) to facilitate the interpretation of pharmacogenetic test results and guide precision medicine

11:30 am - 12:00 pm
Adrian LLerena, Badajoz, Spain – [MedeA]: Development of a Clinical Support System for PGx clinical implementation based of e-health

12:00 pm - 12:30 pm
Maurizio Simmaco, Roma, Italy – Drug-Personal Interaction Network, a bioinformatic tool in the clinical routine: The Italian experience

12:30 pm - 01:00 pm
Belgin Süsleyici, Istanbul, Turkey – Precision Medicine in Routine Turkish Clinical Practice: Today and the Future

01:00 pm – 01:15 pm – CLOSING SESSION – Sofia Siest, Nancy, France